特宝生物(688278.SH)：益佩生新增适应症获得药物临床试验批准通知书

Core Viewpoint - The company Teva Biopharmaceuticals (688278.SH) has received approval from the National Medical Products Administration for a new indication of its product Yipeisheng (generic name: Yipei Growth Hormone Injection) for "Adult Growth Hormone Deficiency (AGHD)" [1] Group 1 - Yipeisheng is a long-acting growth hormone developed by the company, utilizing 40kD Y-type branched polyethylene glycol for single-molecule modification [1] - The product was previously approved for treating growth hormone deficiency in children aged 3 years and older, with market approval expected by May 2025 [1] - The newly approved clinical trial application expands the indication to include treatment for Adult Growth Hormone Deficiency (AGHD) [1]